Biogen said Thursday it will pay more than $1 billion to the biotech firm Denali for rights to a Parkinson’s drug based on an approach that was nearly
Biogen said Thursday it will pay more than $1 billion to the biotech firm Denali for rights to a Parkinson’s drug based on an approach that was nearly
